Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
P 2 (2)

Trial Status

Terminated1
Enrolling By Invitation1
Withdrawn1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07122882Enrolling By Invitation

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

NCT07199959RecruitingPrimary

Study on the Mechanism of Acquired Resistance of Entrectinib

NCT03868423Phase 2Withdrawn

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

NCT02587650Phase 2Terminated

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Showing all 4 trials

Research Network

Activity Timeline